Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B

Trial Profile

Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in HBeAg-positive and HBeAg-negative Chronic Hepatitis B

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms HBRN IA Adult; HBRN Immune Active
  • Most Recent Events

    • 26 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2020.
    • 26 Apr 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2020.
    • 26 Apr 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top